[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-injury":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,45,75,102,128,150,182,213,245,270,295,322,351,382,406,428,455,480,512,536,562,586,609,636,661],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642455","perioperative-myocardial-injury-in-patients-undergoing-coronary-artery-bypass-grafting-a-prospective-clinical-study-100642455",false,"NCT07650487","Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study","Prospective Clinical Study for Evaluation of Perioperative Myocardial Injury Using High-Sensitivity Troponin and Cardiac MRI in Patients Undergoing Coronary Artery Bypass Grafting (CABG)","Inclusion Criteria:\n\n1. Age ≥ 21 years\n2. Undergoing CABG for unstable angina\n3. Able to provide written informed consent\n4. No major cardiovascular event in the prior 6 months\n\nExclusion Criteria:\n\n1. Significant hepatic, renal, or other major organ dysfunction\n2. Pregnancy or breastfeeding\n3. Withdrawal during the study\n4. Contraindication to cardiac MRI (metal implants, claustrophobia, etc.)","ALL","21 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","Perioperative myocardial injury (PMI) following coronary artery bypass grafting (CABG) is associated with postoperative morbidity, mortality, and long-term outcomes. High-sensitivity troponin assays and cardiac MRI offer reliable diagnostic tools for PMI, but evidence regarding optimal diagnostic thresholds and perioperative imaging strategy is limited. This prospective clinical study aims to determine the incidence of perioperative myocardial injury using multimodal assessments including high-sensitivity troponin, electrocardiogram, echocardiography, cardiac MRI, and perioperative cardiovascular events.",[25,26],"Myocardial Injury","Coronary Artery Disease",[28,29,30,31,26],"Perioperative Myocardial Injury","Coronary Artery Bypass Grafting","Cardiac MRI","hs-Troponin","NOT_YET_RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-16","ACTUAL",{"date":38,"type":21},"2026-07-01",{"date":40,"type":21},"2027-07-30",{"name":42,"class":43},"Second Hospital of Jilin University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100398242","troponin-fragmentation-in-myocardial-injury-study-100398242","NCT04465591","TROPOnin FRAGMentation in Myocardial Injury Study","Troponin T Fragmentation in the Assessment of Myocardial Injury Study","Tropo-Fragm","Inclusion Criteria:\n\n* Troponin T fragmentation sample collected from a recruited patient.\n\nExclusion Criteria:\n\n* Age \\\u003C18","18 Years",{"count":55,"type":21},1500,"1 Year","Troponin T (TnT) is a part of the troponin protein complex that principally exists in cardiac and skeletal muscle cells and is widely used as diagnostic biomarker for myocardial injury and, thus, myocardial infarction (MI). Elevated TnT levels can, however, be observed in the presence of other clinical conditions such as heart failure, sepsis and kidney failure and the contemporary high-sensitivity TnT test may yield false positive results when performing diagnostics for suspected MI in these patients.\n\nRecent data have demonstrated that in the presence of MI, TnT gradually undergoes fragmentation into smaller fragments. It has been suggested that in the presence of e.g. chronic kidney disease or physical exercise the released TnT is predominantly in the form of smaller fragments.\n\nHowever, the clinical significance of TnT fragmentation is unknown and, thus, we sought to investigate the prevalence of fragmentation of TnT in different patient cohorts.",[59,25],"Acute Myocardial Infarction Type 1",[61,62,63],"Troponin","myocardial injury","myocardial infarction","RECRUITING","2026-05-04",{"date":67,"type":36},"2026-05-08",{"date":69,"type":36},"2020-04-02",{"date":71,"type":21},"2028-12-31",{"name":73,"class":43},"University of Turku",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":101},"100541023","phase-4-glp-1-receptor-agonist-for-reduction-of-myocardial-injury-after-non-cardiac-surgery-100541023","NCT06324461","GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery","Glucagon-like Peptide-1 Receptor Agonist for Reduction of Myocardial Injury After Non-Cardiac Surgery","GLUMINS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned elective intermediate to high risk non-cardiac surgery\n* Anticipated to remain hospitalized for at least one night after surgery\n* Voluntarily agrees to participate by providing written informed consent\n\nExclusion Criteria:\n\n* History of symptomatic hypoglycemia within 1 month of recruitment\n* History of pancreatitis\n* Diabetic retinopathy\n* Personal or family history of medullary thyroid carcinoma (MTC)\n* Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n* Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment\n* Stroke or transient ischemic attack within 1 month of recruitment\n* Known severe liver disease (Child-Pugh B or C)\n* Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \\\u003C 15 mL\u002Fmin)\n* Recent use of GLP-1 RA within 1 month of recruitment\n* Known allergy or hypersensitivity to GLP-1 RA\n* Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding\n* Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)",{"count":84,"type":21},372,"INTERVENTIONAL",[87],"PHASE4","This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care.\n\nDulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.",[25],[91,92,93],"Myocardial injury following non-cardiac surgery","glucagon-like peptide 1 receptor agonists","Dulaglutide","2026-04-28",{"date":65,"type":36},{"date":97,"type":36},"2024-03-20",{"date":71,"type":21},{"name":100,"class":43},"The University of Hong Kong",3,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":85,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100635176","phase-4-use-dexmedetomidine-to-protect-myocardial-injury-evaluation-100635176","NCT07549282","Use Dexmedetomidine To Protect Myocardial Injury Evaluation","Effects of Preoperative Intranasal Dexmedetomidine on Perioperative Myocardial Injury and Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: A Prospective, Randomized Controlled Trial","UDOPIE","Inclusion Criteria:\n\n* 18 years ≤ age ≤ 85 years;\n* Patients scheduled to undergo elective coronary angiography or percutaneous coronary intervention (PCI);\n* Classified as American Society of Anesthesiologists (ASA) physical status I-III (ranging from patients with mild systemic disease to those with more severe systemic disease that limits normal physical activity but who remain able to perform light daily tasks);\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Allergy or contraindication to dexmedetomidine, such as severe bradycardia (resting heart rate \\\u003C50 beats\u002Fmin), sick sinus syndrome, second-degree or higher atrioventricular block without a pacemaker;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C35% or New York Heart Association functional class III-IV), cardiogenic shock, or hemodynamically unstable patients;\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) or hypotension (systolic blood pressure \\\u003C90 mmHg);\n* Sleep apnea-hypopnea syndrome or Body Mass Index \\>30 kg\u002Fm²;\n* Use of alpha-2 adrenergic receptor agonists (e.g., clonidine) or antagonists, or tricyclic antidepressants, which may affect the action of the study drug, within 1 month before the procedure;\n* Language, visual, or hearing impairment that may affect cognitive assessment;\n* Hepatic or renal insufficiency (Alanine Aminotransferase\u002FAspartate Aminotransferase\u002FCreatinine \\>3 times the upper limit of normal);\n* Anatomical abnormalities of the nasal cavity affecting intranasal drug administration;\n* Pregnant or breastfeeding women.","85 Years",{"count":112,"type":21},1800,[87],"The goal of this clinical trial is to learn if preoperative intranasal dexmedetomidine works to reduce perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). It will also learn about the safety of intranasal dexmedetomidine. The main questions it aims to answer are:\n\nDoes preoperative intranasal dexmedetomidine lower the incidence of perioperative myocardial injury and myocardial infarction after PCI? Does intranasal dexmedetomidine cause safety concerns in patients undergoing PCI? Researchers will compare intranasal dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if intranasal dexmedetomidine works to protect the heart during PCI.\n\nParticipants will:\n\nReceive either intranasal dexmedetomidine (100 μg) or a placebo (normal saline) 15 minutes before the PCI procedure Undergo blood tests to measure cardiac troponin levels before and after the procedure Be followed for up to 30 days after the procedure to record any heart-related events or side effects",[116,25,117,118],"Coronary Heart Disease","Myocardial Infarction","Dexmedetomidine","2026-04-17",{"date":121,"type":36},"2026-04-24",{"date":123,"type":21},"2026-04",{"date":125,"type":21},"2028-04",{"name":127,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":85,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100633800","phase-3-safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-acute-myocardial-injury-following-acute-ischemic-stroke-100633800","NCT07531394","Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex;\n2. AIS confirmed by neuroimaging within 72 hours of symptom onset (or last known well time);\n3. Acute myocardial injury confirmed by serial measurements of plasma cardiac troponin (cTn) within 72 hours of symptom onset \\[19\\];\n4. Written informed consent provided by the participant or their legal authorized representative.\n\nExclusion Criteria:\n\n1. Pre-stroke mRS score ≥ 2;\n2. AIS patients receiving intravenous thrombolysis or endovascular thrombectomy;\n3. Definite history of coronary heart disease, severe valvular heart disease, arrhythmia, heart failure, cardiomyopathy, elevated cTn, and abnormal electrocardiogram (ECG) before onset;\n4. Suspicious cardiac-related symptoms (recurrent\u002Fpersistent chest pain\u002Fchest tightness\u002Fpalpitations, etc.) within 14 days before the index stroke;\n5. Any disorder that could potentially lead to elevated pre-stroke cTn: sepsis, acute kidney injury, rhabdomyolysis, major cardiac surgery or myocardial infarction, previous ischemic or hemorrhagic stroke, congestive heart failure, pulmonary embolism, deep vein thrombosis, endocarditis, severe anemia, thyroid dysfunction, Drug application, etc.;\n6. Patients who are planning for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for the index AMI within 3 months;\n7. Severe liver or kidney dysfunction or malignant tumors;\n8. Uncontrolled hypertension (systolic blood pressure ≥ 200mmHg at enrollment despite medication);\n9. Any limb deformity, vascular or soft tissue injury, orthopedic trauma, or other conditions affecting the implementation of RIC;\n10. Pregnancy or lactation period;\n11. Patients with psychiatric disorders or other reasons unable to cooperate with treatment and follow-up.",{"count":135,"type":21},580,[137],"PHASE3","Introduction: The management of acute myocardial injury following acute ischemic stroke (AMI-AIS), a frequent complication that severely worsens prognosis, is challenging. Remote ischemic conditioning (RIC) has demonstrated therapeutic potential in separate cardiac and cerebrovascular diseases, and preliminary single-center evidence suggests its safety and efficacy in patients with acute ischemic stroke (AIS) complicating acute myocardial infarction. Therefore, we propose to conduct a multicenter, randomized controlled trial to definitively evaluate the safety and efficacy of RIC in patients with AMI-AIS.\n\nMethods: This is a multicenter, randomized, double-blind, sham-controlled trial of 580 participants with AMI-AIS. Participants will be randomized to receive either the RIC procedures or sham RIC procedures twice daily for 14 consecutive days. A 3-month follow-up will be conducted to assess the safety and efficacy of RIC in AMI-AIS patients. The primary study outcome is the incidence of major adverse cardio-cerebrovascular events (MACCEs). The secondary outcomes include mortality, neurological and cardiac function, cerebral infarct volume, and cerebral perfusion.",[140,25],"Ischemic Stroke, Acute","2026-04-09",{"date":143,"type":36},"2026-04-15",{"date":145,"type":21},"2026-05-01",{"date":147,"type":21},"2028-12-01",{"name":149,"class":43},"Capital Medical University",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":85,"phases":160,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":74},"100454534","phase-2-stratified-medicine-of-eplerenone-in-acute-myocardial-infarction-or-injury-and-no-obstructive-coronary-arteries-100454534","NCT05198791","Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.","The Effect of Mineralocorticoid Receptor Antagonist Therapy in Patients With Acute Myocardial Infection or Injury and no Obstructive Coronary Arteries: a Registry-based, Stratified-medicine, Randomized, Controlled Trial","StratMedMINOCA","Inclusion Criteria:\n\n* Age ≥18 years.\n* Acute myocardial infarction or myocardial injury and no obstructive coronary arteries.\n* Cardiovascular risk factor (≥1): age \\>70 years, atrial fibrillation, diabetes, current smoker, eGFR 30 - 60 mL\u002F minute\u002F1.73 m2, prior MI, treated hypertension or COVID-19 (confirmed or suspected)\n* Coronary angiography.\n\nExclusion Criteria (trial):\n\n* Obstructive coronary artery disease\n* Left ventricular ejection fraction ≤40% with evidence of heart failure, following myocardial infarction.\n* Estimated glomerular filtration rate \\\u003C30 mL\u002F minute\u002F1.73 m2\n* Severe liver impairment\n* Women who are pregnant, breast-feeding or of child-bearing potential (WoCBP) without a negative pregnancy test and who are unwilling or unable to follow the reproductive restrictions defined in the eligibility criteria and use highly effective contraception as defined in Appendix 2 for the duration of the study treatment and 30 days after last dose of study drug.\n* Patients taking one of the following medicines :\n* Pre-existing treatment with an MRA :\n* Anti-fungal drugs (ketoconazole or itraconazole).\n* Antiviral medication (nelfinavir or ritonavir).\n* Antibiotics (clarithromycin or telithromycin).\n* Nefazodone used to treat depression.\n* The combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB)) together.\n\nExclusion Criteria (registry):\n\n* Contra-indication to cardiovascular magnetic resonance imaging e.g. severe claustrophobia, metallic foreign body.\n* Contra-indication to intravenous adenosine, i.e. severe asthma; long QT syndrome; second- or third-degree atrio-ventricular block and sick sinus syndrome.\n* Lack of informed consent.",{"count":159,"type":21},400,[161],"PHASE2","Patients with heart attack or heart injury are tested (angiogram) for blockages in their arteries. Patients may develop heart problems caused by damage to small (microvascular) blood vessels. Eplerenone, a mineralocorticoid receptor-selective antagonist, reduces blood vessel injury and is used to treat high blood pressure and heart failure.\n\nAim: to test the use of eplerenone in patients with heart attack\u002Fheart injury an no obstructive coronary arteries and small vessel problems (coronary microvascular dysfunction).\n\nPatients admitted to hospitals in the West of Scotland (2.5 million) and referred for invasive management to the Golden Jubilee and Hairmyres hospitals because of a suspected heart attack heart will be invited to participate into a registry-based clinical trial. Screening, enrolment and verbal, informed consent will be obtained during the angiogram then written consent on the ward. Small vessel disease will be assessed using a 'diagnostic' guidewire during the standard angiogram. People with small vessel problems will be invited to participate in a clinical trial of usual care or eplerenone. Coronary microvascular dysfunction is defined as an index of microvascular resistance ≥25. Coronary flow reserve (CFR abnormal \\\u003C2.0), microvascular resistance reserve ratio (MRR, abnormal \\\u003C2.5), and resistance reserve ratio (RRR abnormal \\\u003C2.0), measured simultaneously with IMR, are predefined parameters of interest.\n\nPatients will be allocated into one of the 3 groups:\n\n* Group 1: Patients without coronary microvascular dysfunction. No eplerenone\n* Group 2: Patient with coronary microvascular dysfunction. Usual care, no eplerenone.\n* Group 3: Small vessels abnormal. Eplerenone tablets.\n\nThe primary outcome for the trial will be reduced heart injury (biomarkers) in patients with microvascular disease. We will also test heart function (MRI scan) at enrolment and at six months. All patients (Groups 1, 2 and 3) will have an angiogram. Standard blood tests will be collected during the hospital stay, and then again at 1 and 6 months. Other outcomes include questionnaires (health status). We will gather information on longer-term health outcomes (hospitalisation, death) using confidential electronic record linkage. We will ask for permission to store blood samples for future research.\n\nThe research will improve scientific knowledge about eplerenone therapy in this patient group. The study will create a repository of clinical samples and images which will provide vital data for studies of endotypes of myocardial infarction or injury with no obstructive coronary arteries.",[164,165,25],"Myocardial Infarction, Acute","Myocardial Infarction With Nonobstructive Coronary Arteries",[167,168,169,170,171,172],"Stratified Medicine","Mineralocorticoid receptor antagonists","MINOCA","Myocardial injury","Myocardial infarction","Myocardial Infarction with Nonobstructive Coronary Arteries","2026-03-12",{"date":175,"type":36},"2026-03-16",{"date":177,"type":36},"2022-02-04",{"date":179,"type":21},"2026-07-31",{"name":181,"class":43},"NHS National Waiting Times Centre Board",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":190,"maxAge":18,"enrollmentInfo":191,"targetDuration":4,"studyType":85,"phases":193,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":44},"100595141","phase-4-effects-of-ciprofol-on-myocardial-injury-after-non-cardiac-surgery-in-video-assisted-thoracoscopic-surgery-100595141","NCT07028593","Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery","Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery (CP-MINS) in Patients Undergoing Video-Assisted Thoracoscopic Surgery: A Randomized, Double-Blind, Propofol-Controlled, Multicenter Trial","CP-MINS","Inclusion Criteria:\n\n1. Scheduled for elective video-assisted thoracoscopic (VATS)-assisted thoracic surgery (lobectomy, segmentectomy, wedge resection of two or more lung tissues, mediastinal tumor resection) under general anesthesia;\n2. Aged 45 to 80 years (inclusive) at the time of randomization;\n3. Expected postoperative hospital stay of ≥3 days;\n4. Signed a written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients allergic to propofol, Ciprofol, or analogs of drug excipient components (soybeans, eggs, milk);\n2. Patients with unstable angina;\n3. Patients with congestive heart failure or hemodynamic instability requiring vasopressor agents;\n4. Patients with severe COPD (FEV1 \\\u003C 1 L);\n5. Glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73m²;\n6. Patients with severe hepatic dysfunction (ALT or AST elevation exceeding 1.5 times the upper limit of normal);\n7. Male or female patients planning to conceive within the next 3 months;\n8. Pregnant or lactating female patients;","40 Years",{"count":192,"type":21},1058,[87],"Myocardial injury after noncardiac surgery (MINS) refers to postoperative elevation of cardiac troponin (cTn) levels caused by underlying ischemic mechanisms (i.e., coronary artery supply-demand imbalance or atherosclerotic thrombosis) without obvious non-ischemic causes (such as pulmonary embolism), with at least one cTn concentration exceeding the 99th percentile of the test reference upper limit, regardless of whether clinical symptoms and ECG changes are present. MINS, including myocardial infarction and ischemic myocardial injury, typically occurs within 30 days after surgery, most commonly within the first 2 postoperative days. It is an independent risk factor for 30-day postoperative mortality and is also closely associated with increased risk of mortality and vascular complications within 2 years . MINS is a common cardiovascular complication after thoracic surgery. Therefore, reducing the incidence of MINS in non-cardiac thoracic surgery to improve patient outcomes is a critical issue in anesthetic management for thoracic surgery.\n\nCiprofol is a Class 1 innovative drug independently developed in China with global intellectual property rights. Currently, Ciprofol has completed Phase III clinical trials in China and the United States; its approved indications in China include sedation or anesthesia for various diagnostic procedures, general anesthesia for surgical operations, and sedation during intensive care unit (ICU) stays. Completed drug clinical trials and published clinical trial data of Ciprofol indicate that it can better maintain circulatory stability and ideal anesthetic depth during anesthesia induction and maintenance, making it a promising intravenous general anesthetic alternative to propofol.\n\nMaintaining hemodynamic stability is an important measure to reduce cardiovascular complications during the perioperative period. Given the good circulatory stability and sedative efficacy of Ciprofol, this study aims to investigate the impact of Ciprofol on MINS in non-cardiac thoracic surgery.",[25,196,197],"Thoracic Diseases","Thoracoscopic Surgery",[199,200,201,202,203],"Myocardial Injury after non-cardiac surgery","Ciprofol","propofol","Video-Assisted Thoracoscopic Surgery","lung tumor","2026-01-26",{"date":206,"type":36},"2026-01-28",{"date":208,"type":36},"2025-07-31",{"date":210,"type":21},"2027-12",{"name":212,"class":43},"Tongji Hospital",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":85,"phases":224,"briefSummary":226,"conditions":227,"keywords":231,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":44},"100618229","steroid-treatment-to-prevent-thoracic-endovascular-aortic-repair-postimplantation-syndrome-100618229","NCT07328906","Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome","Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome (STOP TEVAR PIS): A Randomized, Double-Blind, Placebo-Controlled Trial","STOP TEVAR PIS","Inclusion Criteria:\n\n* Consecutive patients admitted due to endovascular treatment of aortic dissection type B or thoracoabdominal aortic aneurysm in whom elective, open repair is planned.\n* Patients capable of giving informed consent.\n* Patients who are estimated to be available for long-term follow-up.\n\nExclusion Criteria:\n\n* emergency procedures, the existence of severe renal insufficiency (serum creatinine \\>176 µmol\u002FL or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2), severe liver insufficiency (ALT value more than twice the upper limit or bilirubin levels more than twice the reference values), uncontrolled diabetes mellitus (fasting glycemia above 13.9 mmol\u002FL, i.e. the value glycosylated hemoglobin over 8.5%), existence of active infection or sepsis, autoimmune disease, chronic pain syndromes, proven allergy to methylprednisolone, existence of gastric or duodenal ulcer, immunosuppressive or chemotherapy in the previous three months, active malignant disease, genetic diseases of connective tissue, pregnancy, critical lower limb ischemia, previous endovascular procedure on the aorta, preoperative administration of corticosteroids for any reason, significantly impaired cognitive status or psychiatric illness, acute peri\u002Fmyocarditis, advanced heart failure, as well as voluntary refusal to participate in the study","90 Years",{"count":223,"type":21},174,[225],"NA","Postimplantation syndrome (PIS) is a common and clinically important complication following thoracic endovascular aortic repair (TEVAR). PIS is characterized by a strong systemic inflammatory response to the stent-graft implantation and is manifested by flu-like symptoms, which include fever, increased white blood count, increased levels of acute phase proteins, and fatigue, but without a clear inflammatory and infective cause. Besides, it has been demonstrated that PIS is associated with prolonged hospital stay and increased risk for postoperative complications, including acute kidney injury, postoperative delirium, and increased postoperative pain scores. Recently, there has been increasing evidence that PIS is associated with an increased risk of major adverse cardiac events (MACE) and perioperative myocardial injury. Observational studies suggest that preoperative administration of glucocorticoids may decrease the incidence of PIS after TEVAR and EVAR procedures. However, to date, there are no randomised trials that have investigated whether preoperative administration of glucocorticoids can reduce the incidence of PIS and its associated poorer treatment outcomes following TEVAR. This randomized controlled trial was designed to investigate the effect of glucocorticoid administration on reducing the incidence and improving the outcome of patients who develop PIS after TEVAR.",[228,25,229,230],"Postimplantation Syndrome","MACE","Mortality",[232,233,234,62,229,235],"postimplantation syndrome","methylprednisolone","TEVAR","mortality","2026-01-08",{"date":238,"type":36},"2026-01-12",{"date":240,"type":21},"2026-01",{"date":242,"type":21},"2029-01",{"name":244,"class":43},"University of Belgrade",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":253,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":85,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":269},"100419595","hip-fracture-accelerated-surgical-treatment-and-care-track-2-trial-100419595","NCT04743765","HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial","HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial","HIP ATTACK-2","Inclusion Criteria:\n\n1. age ≥45 years;\n2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;\n3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and\n4. informed consent.\n\nExclusion Criteria:\n\n1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;\n2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);\n3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;\n4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);\n5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;\n6. patients refusing consent; or\n7. patients previously enrolled in HIP ATTACK-2.","45 Years",{"count":255,"type":21},1100,[225],"The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.",[259,25],"Hip Fractures","2025-09-25",{"date":262,"type":36},"2025-10-01",{"date":264,"type":36},"2021-11-22",{"date":266,"type":21},"2027-05-31",{"name":268,"class":43},"Population Health Research Institute",70,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":44},"100591590","zeroheart-biopsy---prediction-of-deceased-donor-heart-transplant-performance-from-organ-donors-using-pre-transplant-biopsies---a-pilot-study-100591590","NCT06982404","ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study","ZeroHeart","Inclusion Criteria:\n\nAll hearts from standard and expanded criteria donors as well as donor hearts from Donation after circulatory death (DCD) undergoing a heart biopsy at pre-implantation (at procurement) will be included. Consent will be obtained from the recipient at the time of transplant listing.\n\nExclusion Criteria:\n\nHearts will be excluded from the study if the participating clinician decides to discard the organ before transplantation or the recipient declines that the biopsy will be performed at the organ procurement.",{"count":278,"type":21},50,"The goal of this observational study is to evaluate whether molecular analysis of donor heart biopsies taken at the time of organ removal (\"Time Zero\") can help predict the future function and rejection risk of the transplanted heart in adult transplant recipients.\n\nThe main questions it aims to answer are:\n\n* Can early molecular injury in the donor heart, caused by brain death or circulatory death, be detected at the time of organ removal?\n* Can these early molecular findings predict short-, mid-, and long-term transplant outcomes, such as graft function or rejection?\n\nParticipants will:\n\n* Include heart donors whose hearts are being transplanted (both standard and marginal donors, including DBD and DCD cases)\n* Provide two small biopsies from the donor heart at the time of organ removal: one for routine pathology, one for microarray-based molecular analysis\n* Have routine follow-up biopsies after transplantation as part of standard care (no additional procedures required beyond medical standard)\n\nResearchers will compare biopsy results from different donor types (standard vs. marginal, DBD vs. DCD) to see if early molecular signals are linked to later heart transplant outcomes.",[281,282,25,283,284,285],"Heart Transplantation","Graft Rejection","Organ Preservation","Biopsy","Gene Expression Profiling","2025-05-13",{"date":288,"type":36},"2025-05-21",{"date":290,"type":36},"2025-05-12",{"date":292,"type":21},"2028-05-31",{"name":294,"class":43},"Medical University of Vienna",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":110,"enrollmentInfo":302,"targetDuration":4,"studyType":85,"phases":304,"briefSummary":305,"conditions":306,"keywords":310,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":321},"100434641","crp-apheresis-in-stemi-100434641","NCT04939805","CRP Apheresis in STEMI","Selective C-reactive Protein Apheresis in ST-elevation Myocardial Infarction","Inclusion Criteria:\n\n1. Diagnosis of first acute STEMI in accordance with the European Society of Cardiology (ESC) Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation\n2. Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12 hours prior to primary percutaneous coronary intervention (PCI)\n3. CRP elevation of ≥7 mg\u002Fl measured between 6 to 16 hours after primary PCI\n4. Eligible for primary PCI\n5. Age ≥18 years\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Prior acute myocardial infarction, coronary artery bypass surgery or PCI.\n2. Persistent hemodynamic instability (Killip class \\>2 including cardiogenic shock) or resuscitated cardiac arrest not allowing a CMR scan.\n3. The patient is febrile (temperature \\>38°C) or has experienced an acute infection with fever in the last 14 days.\n4. CRP \\>15 mg\u002Fl at time of hospital admission.\n5. Chronic inflammatory disease.\n6. Known history of severe hepatic failure\n7. Chronic kidney disease with a creatinine clearance \\\u003C30ml\u002Fmin.\u002F1.73m²\n8. Contraindication to CMR.\n9. Pre-STEMI life expectancy of \\\u003C1 year\n10. Participation in another interventional trial\n11. Limited possibility to join the follow-up examinations (e.g. patient lives abroad)\n12. Pregnancy",{"count":303,"type":21},202,[225],"Background: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest. Local and systemic inflammation influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome. C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects the amount of irreversible myocardial tissue damage after acute myocardial infarction.\n\nObjective: The main objectives of the current study are to investigate the efficacy of selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to standard of care for patients with acute STEMI treated with primary PCI.\n\nDesign: Investigator-initiated, prospective, randomized, open-label (outcome assessors masked), controlled, multicenter, two group trial with a two-stage adaptive design.\n\nInnovation: Selective CRP apheresis offers potential to decrease infarct size and consequently improve outcome after PCI for STEMI. This is the first randomized trial investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients. In perspective, the study design allows furthermore to collect robust evidence for the design of a definitive outcome study.",[307,308,309,25],"ST Elevation Myocardial Infarction","C-Reactive Protein","Apheresis",[311],"Cardiac magnetic resonance imaging","2025-05-06",{"date":314,"type":36},"2025-05-09",{"date":316,"type":36},"2021-04-01",{"date":318,"type":21},"2025-08-31",{"name":320,"class":43},"Medical University Innsbruck",5,{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":331,"conditions":332,"keywords":340,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":44},"100589414","mechanisms-and-prognosis-of-stroke-heart-syndrome-100589414","NCT06954103","Mechanisms And Prognosis of Stroke-Heart Syndrome","MAP-SHS","Inclusion Criteria:\n\n1. Patients admitted within 48 hours of onset, confirmed by CT\u002FMRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke).\n2. Moderate-to-severe stroke with NIHSS ≥ 5.\n\nExclusion Criteria:\n\n1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.).\n2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.).\n3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH).\n4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms).\n5. Concomitant systemic diseases such as renal failure (eGFR \\\u003C 30), autoimmune disorders, severe infections, etc.\n6. History of dementia, depression, or other psychiatric disorders.\n7. Poor compliance and inability to cooperate with follow-up.",{"count":330,"type":21},658,"The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.",[333,25,334,335,336,337,338,339],"Stroke","Heart Failure","Acute Coronary Syndromes","Arrhythmia","Sudden Cardiac Death","Takotsubo Syndrome","Heart Rate Variability",[341],"Stroke-heart syndrome","2025-04-23",{"date":344,"type":36},"2025-05-01",{"date":346,"type":36},"2025-03-01",{"date":348,"type":21},"2028-04-01",{"name":350,"class":43},"Chensheng Pan",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":359,"sex":16,"minAge":253,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":85,"phases":362,"briefSummary":363,"conditions":364,"keywords":369,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":44},"100537528","phase-3-colchicine-in-patients-at-cardiac-risk-undergoing-major-non-cardiac-surgery-100537528","NCT06279000","Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery","Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery: Prospective, Randomized, Double-blinded, Placebo-controlled, Multi-centre Study","COLCAT","Inclusion Criteria:\n\nundergoing major non-cardiac surgery in general anaesthesia will be included. Major non-cardiac surgery is defined as:\n\n* vascular surgery (with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies)\n* intraperitoneal surgery\n* intrathoracic surgery\n* major orthopaedic surgery (spinal surgery or joint replacement surgery)\n* at cardiovascular risk, defined as meeting at least 1 of the following 6 criteria:\n\n  * preoperative n-terminal pro brain natriuretic peptide (NT-proBNP) ≥ 200 ng\u002Fl\n  * history of coronary artery disease\n  * history of peripheral vascular disease\n  * history of stroke\n  * undergoing major vascular surgery, with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies\n  * fulfilment of any 3 of the 8 following criteria:\n\n    * undergoing major surgery (intrathoracic, intraperitoneal or supra-inguinal vascular surgery)\n    * any history of congestive heart failure or history of pulmonary oedema\n    * anamnestic transient ischemic attack (TIA)\n    * diabetes under treatment with either oral antidiabetic agent or insulin\n    * age \\> 70 years\n    * history of hypertension\n    * serum creatinine \\> 175 mumol\u002Fl or calculated creatinine clearance \\< 60 ml\u002Fmin\u002F1.73m2 (cockcroft gault)\n    * history of smoking within 2 years of surgery\n    * planned surgical time ≥ 90 minutes\n    * planned postoperative hospital stay at least 1 night\n\nExclusion Criteria:\n\n* no written consent\n* inclusion in other clinical trial with direct impact on perioperative medication\n* previously reported side effects or reported intolerance from colchicine (e.g., allergic reaction or significant sensitivity to colchicine or an auxiliary substance of the IMP)\n* pregnancy or planned pregnancy and\u002For breast feeding\n* clinically significant history of drug or alcohol abuse within the last year\n* very severe frailty (≥ 8 clinical frailty scale)\n* patient with inflammatory bowel disease (e.g., Morbus Crohn or Colitis ulcerosa)\n* patient taking colchicine for other indications (e.g., familial Mediterranean fever, gout)\n* severe renal impairment (eGFR \\< 30 ml min -1 1.73 m2 -1) or end-stage renal disease with indication for haemodialysis\n* history of solid organ or bone marrow transplantation\n* systemic immune-suppression (medication (steroids \\>30mg cortisol-equivalent per day, tacrolimus etc...) or disease (e.g., myelodysplastic syndrome)\n* severe hepatic impairment with history of cirrhosis\n* chronic active hepatitis or functional disorders defined as alanine aminotransferase greater than three times the upper limit of normal\n* anticipated post-operative administration of CYP3A4 metabolized substances like cyclosporine, ketoconazole, clarithromycin, verapamil, quinidine, diltiazem or ritonavir\n* Any other condition that the investigator would consider a risk to the patient if the latter were to participate in the study.",true,{"count":361,"type":21},880,[137],"Perioperative myocardial injury and major adverse cardiovascular events (MACE) are common causes of morbidity and mortality in patients at increased cardiovascular risk undergoing non-cardiac surgery.\n\nHowever, research in recent years has yielded limited preventive and therapeutic measures for myocardial injury\u002FMACE. Recent studies in patients with chronic and acute coronary artery disease have shown that colchicine administration can reduce the risk of cardiovascular events.\n\nThese encouraging results in non-surgical patients ask for a similar investigation in patients undergoing major non-cardiac surgery. The aim of the proposed study is to investigate the effects of perioperative colchicine administration on the incidence of myocardial injury\u002FMACE.",[365,366,367,25,368],"Cardiovascular Diseases","Cardiovascular Complication","Perioperative Complication","Myocardial Injury After Noncardiac Surgery (MINS)",[370,62,371,372],"Perioperative Cardiovascular Risk","major adverse cardiac events","colchicine","2025-04-19",{"date":375,"type":36},"2025-04-24",{"date":377,"type":36},"2025-04-20",{"date":379,"type":21},"2029-03-30",{"name":381,"class":43},"Cantonal Hospital of St. Gallen",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":85,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":44},"100420121","phase-2-nad-augmentation-in-cardiac-surgery-associated-myocardial-injury-trial-100420121","NCT04750616","NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial","NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) Trial","NACAM","Inclusion Criteria\n\n* Informed consent before any study-related activities.\n* Men or women \\>18 years of age who are scheduled for non-emergent cardiac surgery procedures requiring CPB and are at increased risk for surgery-related adverse cardiovascular outcomes.\n\nProcedures include:\n\n* CABG\n* Aortic, mitral, tricuspid, or pulmonic valve replacement or repair\n* CABG with aortic, mitral, tricuspid, and\u002For pulmonic valve replacement\n\nRisk factors for surgery related to adverse cardiovascular outcomes include one or more of the following:\n\n* Valve surgery\n* eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m2\n* Documented LVEF ≤ 35% within six months before surgery\n* Documented history of heart failure\n* Insulin-requiring diabetes\n* Non-insulin-requiring diabetes and the presence of ≥+2 proteinuria on urinalysis (or equivalent on urine protein-to-creatinine ratio or urine albumin-to-creatinine ratio)\n* Preoperative anemia (hemoglobin \\\u003C11g\u002Fdl for men and women)\n* History of prior CABG\n* Age ≥65\n\nExclusion Criteria\n\n* Preexisting AKI within seven days before surgery as defined by KDIGO stage ≥1 (serum creatinine-based)\n* Kidney transplant status\n* Off-pump cardiac surgery\n* ESRD\n* Emergent cardiac surgery\n* Pregnancy\n* Patient enrolled in competing research studies that may affect outcomes\n* Patients held in an institution by legal or official order",{"count":391,"type":21},304,[161],"A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery",[395,25,396],"Ischemia Reperfusion Injury","Acute Kidney Injury","2025-03-10",{"date":399,"type":36},"2025-03-12",{"date":401,"type":36},"2021-09-13",{"date":403,"type":21},"2025-06-30",{"name":405,"class":43},"Kaiser Permanente",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":359,"sex":16,"minAge":53,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":85,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":424,"leadSponsor":426,"locationsCount":44},"100578249","sufentanil-in-patients-with-lower-extremity-fracture-surgery-myocardial-damage-function-study-100578249","NCT06808841","Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study","Sufentanil is Paired Via the BMP6\u002FSMAD Pathway Cardiac Injury in Lower Extremity Fracture Surgery Function Study","Sipwlefsmdfs","Inclusion Criteria:\n\n* There were 160 patients aged 18-65 years and older who needed surgery for lower extremity fracture.\n* ASA grades I to III, gender is not limited.\n\nExclusion Criteria:\n\n* Patients with acute myocardial infarction in the last 6 months, those with a history of heart failure, and those with elevated troponin levels before injury.\n* Old fracture\n* Stroke patients\n* Liver cirrhosis, kidney failure\n* Serious systemic infections, alcoholism, drug dependence\n* Pathological fracture\n* Use of glucocorticoids in the past one month\n* Diabetic","65 Years",{"count":416,"type":21},160,[225],"1. To analyze the association of different doses of opioids on myocardial injury\u002Fprotection through BMP-6\u002FSMAD pathway.\n2. To observe the effect of different doses of opioids on the expression of BMP-6 in bone marrow.\n3. To investigate the relationship between different doses of opioids and BMP-6 and perioperative cardiovascular adverse events in patients with lower extremity fracture surgery.",[25],"2025-02-04",{"date":422,"type":36},"2025-02-05",{"date":422,"type":21},{"date":425,"type":21},"2025-05-10",{"name":427,"class":43},"Second Hospital of Shanxi Medical University",{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":85,"phases":438,"briefSummary":439,"conditions":440,"keywords":444,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":4},"100572662","phase-4-the-cardioprotective-effects-of-improving-potassium-variability-in-maintenance-hemodialysis-patients-100572662","NCT06736184","the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","A Prospective Multicenter Randomized Controlled Trial on the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n1. Age 18-75 years old;\n2. Maintenance hemodialysis ≥3 months;\n3. Serum potassium ≥5.0mmol\u002FL and ≤8mmol\u002FL before dialysis;\n4. Have independent ability;\n5. Complete clinical baseline data.\n\nExclusion Criteria:\n\n1. Complicated with congenital heart disease, myocardial infarction and other heart diseases that may lead to cardiac dysfunction;\n2. Combined with other serious diseases, such as immune diseases, severe liver and kidney dysfunction;\n3. Unable to cooperate with the researcher due to mental reasons;\n4. If the duration of dialysis is less than 4 hours, severe infection;\n5. Patients with malignant tumors or major mental disorders;\n\n6, except primary cardiomyopathy;\n\n7\\. Severe constipation, intestinal obstruction, etc.\n\n8\\. other investigators considered that enrollment was not recommended.","75 Years",{"count":437,"type":21},100,[87],"The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. This measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. Hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in MHD patients. Due to the intermittent nature of hemodialysis treatment, MHD patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of MHD patients. Serum potassium variability can better reflect the potassium homeostasis in MHD patients. In addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of MHD patients. At present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. In this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.",[441,442,443,25],"Chronic Kidney Disease on Hemodialysis","Hypokalemia","Hyperkalemia",[445,446,170],"maintenance hemodialysis","Potassium Variability","2024-12-12",{"date":449,"type":36},"2024-12-16",{"date":346,"type":21},{"date":452,"type":21},"2026-12-31",{"name":454,"class":43},"Qianfoshan Hospital",{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":359,"sex":16,"minAge":253,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":464,"conditions":465,"keywords":468,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":44},"100499109","endothelial-dysfunction-and-non-cardiac-surgery-100499109","NCT05778981","Endothelial Dysfunction and Non-cardiac Surgery","Endothelial Dysfunction During Non-cardiac Surgery and Major Clinical Events","Inclusion Criteria:\n\n* Signed informed consent\n* Patients 45 years or older\n\nExclusion Criteria:\n\n* Refuse to participate in the study\n* Myocardial injury or acute myocardial infarction less than two weeks ago\n* Patients who expect less than 2 days of hospitalization\n* Patients in whom the troponin elevation is attributed to a secondary cause (for example, sepsis, pulmonary thromboembolism, electrical cardioversion, etc.)\n* Use of chemotherapy less than 2 weeks ago",{"count":463,"type":21},200,"Endothelial dysfunction is a cardiovascular disease hallmark. After non-cardiac surgery, cardiovascular events correlate with surgical outcomes. Understanding the role of endothelial function in these events is crucial.\n\nThis research aims to study endothelial function and its association with cardiovascular events.",[466,467,333,25],"Surgery","Cardiac Death",[469,470,61],"FMD","Flow-Mediated Dilatation","2024-12-05",{"date":473,"type":36},"2024-12-10",{"date":475,"type":36},"2023-03-25",{"date":477,"type":21},"2025-12-01",{"name":479,"class":43},"University of Chile",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":487,"targetDuration":4,"studyType":85,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":44},"100570267","phase-2-study-to-assess-safety-and-efficacy-of-treating-symptomatic-ischemic-chronic-congestive-heart-failure-patients-with-an-lvef-of-40-with-fresh-uncultured-autologous-adipose-derived-regenerative-cells-isolated-from-lipoaspirate-100570267","NCT06705023","Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.","Adipose-derived Regenerative Cells Treatment for Congestive Heart Failure","Inclusion Criteria\n\n* Have documented coronary artery disease with evidence of myocardial injury, LV dysfunction, and clinical evidence of heart failure\n* Have an EF ≤40% by cardiac MRI\n* Be receiving guideline-driven medical therapy for heart failure at stable and tolerated doses for ≥1 month before consent\n* Be a candidate for right heart cardiac catheterization\n* Have New York Heart Association class I, II, or III heart failure symptoms\n* If a female of childbearing potential, be willing to use one form of birth control for the duration of the study, and undergo a pregnancy test at baseline and within 36 h before treatment\n\nExclusion Criteria\n\n* Indication for standard-of-care surgery (including valve surgery, placement of LV assist device, or imminent heart transplantation), CABG procedure, and PCI. Candidates cannot be UNOS 1A or 1B, and they must have documented low probability of being transplanted.\n* PCI within 3 months of randomization\n* CABG within 3 months of randomization\n* Valvular heart disease including mechanical or bioprosthetic heart valve, severe valvular (any valve) insufficiency\u002Fregurgitation within 12 month of consent, and aortic stenosis with valve area ≤1.5 cm2\n* History of ischemic or hemorrhagic stroke within 90 d of consent\n* History of an LV remodeling surgical procedure utilizing prosthetic material\n* Presence of a pacemaker and ICD generator with any of the following limitations\u002Fconditions: manufactured before the year 2015\n* Leads implanted \\\u003C6 week before consent\n* Non-transvenous epicardial or abandoned leads\n* Subcutaneous ICDs\n* Leadless pacemakers\n* Pacemaker-dependence with an ICD (pacemaker-dependent candidates without an ICD are not excluded)\n* Any other condition that, in the judgment of device-trained staff, would deem an MRI contraindicated\n* A CRT device implanted within 3 months of consent\n* An appropriate ICD firing or antitachycardia pacing for ventricular fibrillation or ventricular tachycardia within 30 days of consent\n* Ventricular tachycardia (≥20 consecutive beats) without an ICD within 3 month of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent\n* Presence of LV thrombus\n* Baseline eGFR \\\u003C35 mL\u002Fmin per 1.73 m2\n* Poorly controlled blood glucose levels (HbA1c \\>10%)\n* Hematologic abnormality evidenced by hematocrit \\\u003C25%, white blood cell \\\u003C2500 per μL, or platelet count \\\u003C100 000 per μL\n* Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3× the ULN\n* Coagulopathy (INR ≥1.3) not due to a reversible cause (eg, warfarin and factor Xa inhibitors). Patients who cannot be withdrawn from anticoagulation will be excluded.\n* HIV or active HBV or HCV\n* Allergy to radiographic contrast material that cannot adequately be managed by premedication\n* Known history of anaphylactic reaction to penicillin or streptomycin\n* Received gene or cell-based therapy from any source within the previous 12 months\n* History of malignancy within 3 years, excluding basal cell carcinoma or cervical carcinoma in situ which have been definitively treated\n* Condition that limits expected lifespan to \\\u003C1 year\n* History of drug or alcohol abuse\n* Chronic immunosuppressant therapy such as corticosteroids or TNF-α antagonists\n* Cognitive or language barriers that prohibit obtaining informed consent or any study elements\n* Pregnancy or lactation or plans to become pregnant in the next 12 months\n* Conditions that, in the judgment of the Investigator or Sponsor, would impair enrollment, cell harvest, administration or follow-up\n\nALT indicates alanine aminotransferase; AST, aspartate aminotransferase; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ICD, implantable cardioverter defibrillator; INR, international normalized ratio; LV, left ventricular; MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention; TNF-α, tumor necrosis factor-α; ULN, upper limit of normal; UNOS, United Network for Organ Sharing; and Vo2 max, maximal oxygen consumption.",{"count":488,"type":21},36,[161],"To investigate patients suffering from iHF and a LVEF of equal or less than 40% despite best medical treatment safety and efficacy of a single retrograde intra-cardiac venous (i.cv.) injection of UA-ADRCs isolated from lipoaspirate at the point of care, using the Transpose® RT \u002F Matrase System (InGeneron, Houston, TX, USA) through an over-the- wire, small balloon catheter, advanced through the coronary si-nus and located within a coronary vein at the site of inter-est, versus patients on best medical treatment.",[25,492,26,334],"LV Dysfunction",[494,495,496,497,498,499,500,501,502],"congestive heart failure","adipose-derived regenerative cells","left ventricular ejection fraction","lipoaspirate","retrograde intra-cardiac venous injection","Cardiac Magnetic Resonance Imaging","Cardiac Computer Tomography","end systolic volume","end diastolic volume","2024-11-28",{"date":505,"type":36},"2024-12-03",{"date":507,"type":36},"2024-11-18",{"date":509,"type":21},"2025-12-31",{"name":511,"class":43},"Ralf Rothoerl",{"id":513,"slug":514,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":519,"targetDuration":4,"studyType":85,"phases":521,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":535},"100538851","phase-3-study-of-intravenous-tad-600-mg4-ml-solution-for-injection-to-evaluate-efficacy-and-safety-in-preventing-myocardial-injury-in-patients-with-pneumonia-100538851","NCT06296212","Study of Intravenous TAD® 600 Mg\u002F4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.","Multicenter, Randomized, Double-blind, Phase III Study of Intravenous TAD® 600 Mg\u002F4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.","Inclusion Criteria\n\n* Patients with an age of ≥ 18 and ≤ 80 years\n* Diagnosis of CAP or HAP requiring hospitalization\n* Patients with one of the following :\n\n  \\- At least one cardiovascular comorbidity:\n* Chronic atrial fibrillation\n* History of ischemic heart disease (≥ 3 months)\n* Heart failure\n* Cardiac Valvular Disease\n* Previous (≥ 6 months) episode of myocarditis or pericarditis.\n\n  \\- Very high risk of developing cardiovascular diseases according to the SCORE2 and SCORE2-OP risk models for moderate risk European regions (score ≥ 7.5% for patients \\\u003C 50 years old, score ≥ 10% for patients 50-69 years old, and score ≥ 15% for patients ≥ 70 years old).\n* Provision of written informed consent as approved by the Ethics Committee (EC).\n\nExclusion Criteria\n\nMedical Conditions:\n\n* Active malignancy\n* Severe heart failure (NYHA class III and IV)\n* End-stage renal failure (eGFR \\\u003C 30 mL\u002Fmin)\n* Severe liver disease\n* History of hypersensitivity to glutathione or any excipients\n* Use of drugs containing sacubitril\n* Use of drugs with antioxidant activity in the last 3 months\n* Use of narcotics\n* Use of invasive mechanical ventilation\n* Recent (\\\u003C 3 months) ACS (STEMI, NSTEMI, UA), myocardial revascularization, myocarditis, acute pericarditis episodes.\n\nGeneral Conditions:\n\n* Pregnant or breastfeeding women\n* Women of child-bearing potential not using at least one effective contraceptive method for the entire trial\n* Participation in other investigational drug or device clinical trials within 30 days prior to study screening\n* Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial\n* Patients unable or unwilling to comply with the appointments after hospitalization or with all the requirements of the Protocol.",{"count":520,"type":21},178,[137],"The goal of this PHASE III clinical trial is to evaluate efficacy and safety of intravenous TAD® 600 mg\u002F4 mL solution for injection in preventing myocardial injury in patients with pneumonia.\n\nThe main question it aims to answer is:\n\n• could TAD® used as an add-on treatment to the standard therapy, due to the presence of the sodium salt glutathione, be effective and safe in preventing the risk of developing myocardial injury in hospitalized patients with pneumonia?\n\nPatients diagnosed with pneumonia (in the emergency department or hospital ward) will be asked to participate in the study and sign the Informed Consent Form (ICF) to assess their eligibility for enrollment.\n\nEligible patients who meet the study inclusion criteria and complete the required Screening \\& Baseline (V0) examinations, will be randomized with a 1:1 ratio allocation to the IMP Test group (TAD® treatment) or IMP Placebo group (Placebo treatment) in a double-blind manner, PI \\& Patient blinded.\n\nTAD® (600 mg\u002F4 mL reconstituted solution in 50 mL of 0.9% sodium chloride solution) or Placebo (50 mL of 0.9% sodium chloride solution) will be administered:\n\n* intravenously (with an infusion rate of 10 mL\u002Fmin)\n* 2 times a day (with a dosing interval of 8 hours ± 30 minutes)\n* for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5)\n* patients will then be required to undergo five Follow-up Visits.",[524,25],"Pneumonia","2024-11-25",{"date":527,"type":36},"2024-11-27",{"date":529,"type":36},"2024-06-25",{"date":531,"type":21},"2025-09-30",{"name":533,"class":534},"Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica","INDUSTRY",7,{"id":537,"slug":538,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":543,"enrollmentInfo":544,"targetDuration":4,"studyType":85,"phases":545,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":4},"100545267","resonance-breathing-training-for-long-covid-related-myocardial-injury-100545267","NCT06379672","Resonance Breathing Training for Long Covid-related Myocardial Injury","An Investigation of the Efficacy of Resonance Breathing Training in the Rehabilitation of Patients with Long Covid-related Myocardial Injury","Inclusion Criteria:\n\n1. Age between 18 and 60 years;\n2. According to the WHO definition: one or more systemic involvement present 3 months after the diagnosis of a new crown infection, and at least 2 of these months cannot be explained by other diseases\n3. 2D-STE suggestive of GLSAVG: -17% ≤ men ≤ -10%, -18% ≤ women ≤ -10%;\n4. Consent for enrollment based on the degree of myocardial injury, as diagnosed by a clinician;\n5. Signing the informed consent form with the consent of the patient or his\u002Fher family members\n\nExclusion Criteria:\n\n* (1) Previous history of coronary atherosclerotic heart disease and heart failure; (2) Combination of severe arrhythmia or cardiogenic shock; (3) Combination of severe hypertension, hypertrophic cardiomyopathy, valvular disease of moderate or higher grade, acute myocarditis or pericarditis; (4) Combination of any disease that severely affects limb movement, such as musculoskeletal system disease or severe hepatic or renal insufficiency; (5) Combination of progressive malignant tumors, infectious diseases, bleeding disorders, autoimmune diseases, etc; Those who have serious mental illness and are unable to cooperate","60 Years",{"count":269,"type":21},[225],"An investigation of the efficacy of resonance breathing training in the rehabilitation of patients with Long covid-related myocardial injury",[548,25],"Long COVID",[550,551,25,552],"2D-STE","resonance breathing","Long Covid-19","2024-07-29",{"date":555,"type":36},"2024-07-30",{"date":557,"type":21},"2024-08-25",{"date":559,"type":21},"2024-10-05",{"name":561,"class":43},"Chengdu Sport University",{"id":563,"slug":564,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":569,"conditions":570,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":44},"100400137","carbon-monoxide-intoxication-in-korea-prospective-cohort-care-co-cohort-100400137","NCT04490317","CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)","Inclusion Criteria:\n\n* Acute CO poisoning\n\nExclusion Criteria:\n\n* Declined to enrollment in the study",{"count":55,"type":21},"This prospective cohort study enrolls subjects who experience carbon monoxide (CO) poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments and short and long-term outcomes in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through various ways and the association between complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.",[571,25,572,573,574,575,576],"Carbon Monoxide Poisoning","Neurologic Deficits","Image, Body","Therapy","Prognostic Factors","Complications","2024-07-22",{"date":579,"type":36},"2024-07-23",{"date":581,"type":36},"2020-07-29",{"date":583,"type":21},"2035-12",{"name":585,"class":43},"Wonju Severance Christian Hospital",{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":359,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":44},"100554975","characterization-of-acute-myocardial-damage-with-spectral-computed-tomography-cadami-spectral-100554975","NCT06506071","Characterization of Acute Myocardial Damage With Spectral Computed Tomography. (CADAMI-SPECTRAL)","Characterization of Acute Myocardial Damage With Spectral Computed Tomography. CADAMI-SPECTRAL.","CADAMI","Inclusion Criteria:\n\n* Age ≥ 18 year.\n* Hospital admission due to chest pain and acute myocardial injury.\n* Clinical indication for cardiac MRI (CMR) due to suspected acute myocardial infarction with coronary angiography showing no significant lesions (\\\u003C50%) (MINOCA), acute myocarditis, or stress-induced cardiomyopathy.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Contraindications to undergo cardiac MRI and CT with administration of gadolinium and\u002For iodine-based contrast, respectively.\n* Pre-existing cardiomyopathy.\n* Pre-existing chronic ischemic heart disease.\n* Invasive coronary angiography showing coronary lesions ≥50%.",{"count":595,"type":21},300,"Clinical management of patients with chest pain and elevation of biomarkers of myocardial injury require an accurate diagnosis. Until now, cardiac magnetic resonance imaging (cMRI) is the gold standard for the diagnosis among myocarditis, stress cardiomyopathy, or inapparent ischemic damage. The development of spectral CT has opened up the possibility of characterizing the coronary anatomy and the myocardium in a single procedure. Our aim is to assess the diagnostic ability of differential patterns in first- pass perfusion and delayed iodine enhancement obtained by spectral CT in patients with acute myocardial injury. This study is designed as a prospective multicenter observational study with diagnostic intervention in 150 patients admitted with clinical indication of a cMRI due to suspicion of myocardial infarction with normal coronary arteries (MINOCA), myocarditis or stress cardiomyopathy who will undergo a CT study with double detector technology in two reference centers. A control group (n=150) with an indication for cardiac CT for another cause without coronary or structural heart disease will be included. The iodine maps obtained by spectral CT will be compared with the findings obtained with cMRI, both with conventional techniques and with artificial intelligence algorithms (deep learning). A year follow-up of the cohort will be carried out to assess whether the findings derived from the CT in this group of patients provide prognostic information",[598,599,600,25],"Myocarditis; Acute or Subacute","Takotsubo Cardiomyopathy","Infarction, Myocardial","2024-07-19",{"date":579,"type":36},{"date":604,"type":36},"2022-09-01",{"date":606,"type":21},"2025-09-01",{"name":608,"class":43},"Salamanca University Hospital",{"id":610,"slug":611,"hasResults":11,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":221,"enrollmentInfo":617,"targetDuration":4,"studyType":85,"phases":619,"briefSummary":620,"conditions":621,"keywords":623,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":74},"100479188","lymphatic-organs-and-myocardium-after-myocardial-infarction-100479188","NCT05519735","Lymphatic Organs and Myocardium After Myocardial Infarction","Multimodal Characterization of Lymphatic Organs and Myocardium in Patients After Acute Myocardial Infarction","LOMI","Inclusion Criteria:\n\n* patients with acute myocardial infarction (STEMI) who were treated with immediate catheterization\n* stable clinical course\n* male\u002Ffemale, above 18 years old\n\nExclusion Criteria:\n\n* hemodynamic instablity \\> 48 h after immediate catherization\n* known CAD\n* known structural heart disease\n* multi vessel disease\n* NSTEMI\n* sarcoidosis\n* immunosuppressive therapy\n* acute inflammatory disease\n* no consent obtainable\n* contraindiations for CMR\n* impaired renal function\n* active cardiac implants, ferromagnetic implants\n* pregnancy, breast-feeding",{"count":618,"type":21},57,[225],"The adaptive immune response plays an important role in myocardial healing and remodeling after acute myocardial infarction in patients. Therefore, the involved lymphocytes represent a novel target for therapeutic interventions. However, there are no established blood-derived biomarkers to predict the quantity and quality of the adaptive immune response to cardiac injury. Multimodal imaging of the heart and immunologic organs might provide such information.\n\nRecent retrospective analysis of patients after MI revealed enlarged mediastinal lymph nodes associated with increased CXCR4 radiotracer accumulation, thereby indicating that CXCR4 PET-based lymph node imaging provides a non-invasive quantitative readout of the local adaptive immune response. These considerations are further fuelled by the fact that, within lymph nodes, CXCR4 is expressed almost exclusively on lymphocytes, whereas various other cell types express CXCR4 within the myocardium.\n\nThis leads to the hypothesis that the size of mediastinal lymph nodes and their respective CXCR4 PET signals correlate with the adaptive immune response to cardiac injury and might provide predictive information for functional cardiac decline during follow-up.\n\nThis prospective clinical study will use multimodal imaging to monitor chemokine receptor 4 (CXCR4) expression in the lymph nodes, myocardium, spleen, and bone marrow after acute MI. The combination of cardiac magnetic resonance (CMR), echocardiography, and positron emission tomography (PET) along with blood collection for immunophenotyping will allow to determine i) if the size of mediastinal lymph nodes and their respective PET-derived CXCR4 signals at baseline correlate with the adaptive immune response to acute cardiac injury; and ii) if they predict cardiac adverse remodelling during longitudinal follow-up.",[117,25,622],"Myocardial Inflammation",[624,625,626,117],"CXCR4","CMR","Lymphatic organs","2023-05-24",{"date":629,"type":36},"2023-05-25",{"date":631,"type":36},"2022-04-01",{"date":633,"type":21},"2026-12",{"name":635,"class":43},"Wuerzburg University Hospital",{"id":637,"slug":638,"hasResults":11,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":11,"sex":16,"minAge":414,"maxAge":221,"enrollmentInfo":643,"targetDuration":4,"studyType":85,"phases":645,"briefSummary":646,"conditions":647,"keywords":650,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":44},"100488112","phase-4-effects-of-low-dose-esmolol-on-myocardial-injury-after-non-cardiac-surgery-in-elderly-frail-patients-100488112","NCT05635877","Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients","Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients:A Multicenter, Prospective, Double-blind, Randomized Controlled Study","Inclusion Criteria:\n\n1. Age ≥ 65 years;\n2. ASA: ⅰ-ⅳ;\n3. Modified frailty index (mFI) ≥ 0.21;\n4. Patients undergoing non-cardiac surgery.\n\nExclusion Criteria:\n\n1. Refuse to participate;\n2. Expected hospital stay \\\u003C3 days;\n3. Preoperative β-blocker therapy;\n4. History of myocardial infarction or coronary artery disease;\n5. Preoperative bradycardia (heart rate \\[HR\\] \\\u003C 50 bpm) or arrhythmia;\n6. Significant cardiac insufficiency (i.e., pulmonary artery pressure \\>18 mm Hg, cardiac index ≤ 2.2 L\u002Fmin\u002Fm 2);\n7. Severe valvular heart disease;\n8. Severe lung disease (e.g. asthma or chronic obstructive pulmonary disease);\n9. Patients with perioperative troponin elevation due to nonischemic causes (e.g., sepsis, pulmonary embolism, arrhythmia);\n10. The same patient can only be included once, regardless of whether the reason for the second operation is related to the first cause.\n\n    \\-",{"count":644,"type":21},2000,[87],"This topic will focus on the following questions:\n\n1. Part one: To clarify the relationship between preoperative frailty and myocardial injury (cTnT ≥0.03) after non-cardiac surgery in elderly patients; To further explore the predictive factors of myocardial injury after non-cardiac surgery （MINS） in elderly frail patients before operation.\n2. Part Two: To explore the effect of low-dose esmolol on myocardial injury after non-cardiac surgery in frail elderly patients.",[648,649,25],"Frailty","Esmolol",[651],"myocardial injury after non-cardiac surgery, MINS","2023-03-27",{"date":654,"type":36},"2023-03-29",{"date":656,"type":36},"2023-02-07",{"date":658,"type":21},"2026-12-30",{"name":660,"class":43},"Yongtao Sun",{"id":662,"slug":663,"hasResults":11,"nctId":664,"briefTitle":665,"officialTitle":665,"acronym":4,"eligibilityCriteria":666,"healthyVolunteers":11,"sex":16,"minAge":414,"maxAge":667,"enrollmentInfo":668,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":670,"conditions":671,"keywords":674,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":682,"locationsCount":74},"100423338","singapore-perioperative-ageing-study-sing-pas-100423338","NCT04792554","Singapore Perioperative Ageing Study (Sing-PAS)","Inclusion Criteria:\n\n* Elderly patients aged 65 years and above\n* Undergoing major non-cardiac surgery, defined as surgery that is predicted to be at least 2 hours and requiring at least 1 day postoperative stay in the hospital\n* English, Chinese or Malay speaking\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* History of psychiatric disease\n* Illiterate\n* An active history of substance abuse.\n* Undergoing neurological procedures\n* Undergoing emergency surgeries\n* Has a second surgery planned within 5 days of index surgery\n* Non-resident of Singapore\n* Severe hearing and\u002For speech impairment","100 Years",{"count":669,"type":21},600,"The specific aim of the study will be to set up a perioperative database to longitudinally track the progress of elderly patients undergoing major surgery from the preoperative period to five years postoperatively. This database will form the foundation of a programme that will be sustainable through future grants to implement clinical strategies to improve outcomes.",[672,673,25],"Postoperative Delirium","Aging",[675],"Geriatrics","2022-10-04",{"date":678,"type":36},"2022-10-06",{"date":680,"type":36},"2021-04-07",{"date":633,"type":21},{"name":683,"class":43},"National University Hospital, Singapore"]